Merge Healthcare (Nasdaq: MRGE ) is expected to report Q4 earnings around Feb. 10. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Merge Healthcare's revenues will grow 0.9% and EPS will drop -50.0%.
The average estimate for revenue is $64.7 million. On the bottom line, the average EPS estimate is $0.02.
Last quarter, Merge Healthcare reported revenue of $60.4 million. GAAP reported sales were 0.5% higher than the prior-year quarter's $60.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.01. GAAP EPS were -$0.04 for Q3 versus -$0.01 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 62.0%, 180 basis points worse than the prior-year quarter. Operating margin was 10.0%, 470 basis points worse than the prior-year quarter. Net margin was -6.3%, 460 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $249.7 million. The average EPS estimate is $0.08.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 110 members out of 131 rating the stock outperform, and 21 members rating it underperform. Among 36 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 31 give Merge Healthcare a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Merge Healthcare is hold, with an average price target of $4.58.
Is Merge Healthcare the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.